INNOGEN-B (02591) has released its interim results for the six months ended June 30, 2026. The group recorded revenue of RMB 78.218 million, representing a year-on-year increase of 38.57%. The loss attributable to owners of the parent company stood at RMB 115 million, narrowing by 5.72% compared to the prior year, with a loss per share of RMB 0.25.

According to the announcement, the group commercially launched Yisupaglutide alfa for the treatment of type 2 diabetes (T2D) in mainland China in February 2025, followed by Macau in September 2025. Following the inclusion of Yisupaglutide alfa in the National Reimbursement Drug List for the treatment of adult T2D in December 2025 (effective from January 1, 2026), the drug has continued to gain market coverage and commercial momentum.

Where to begin

Investors may want to monitor the drug's post-reimbursement sales trajectory, as market penetration and prescription volumes will be critical indicators of the company's ability to convert coverage into sustained revenue growth.

Why focus on this single entity

Given the company's concentrated product pipeline, its financial performance is highly sensitive to the commercial success of Yisupaglutide alfa. As such, tracking its quarterly sales data and market access expansion could provide clearer visibility into the company's path toward profitability.